GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » PB Ratio

Nkarta (Nkarta) PB Ratio : 1.12 (As of May. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nkarta PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-13), Nkarta's share price is $6.25. Nkarta's Book Value per Share for the quarter that ended in Dec. 2023 was $5.56. Hence, Nkarta's PB Ratio of today is 1.12.

The historical rank and industry rank for Nkarta's PB Ratio or its related term are showing as below:

NKTX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 4.35
Current: 1.12

During the past 6 years, Nkarta's highest PB Ratio was 4.35. The lowest was 0.00. And the median was 0.00.

NKTX's PB Ratio is ranked better than
77.65% of 1311 companies
in the Biotechnology industry
Industry Median: 2.5 vs NKTX: 1.12

During the past 12 months, Nkarta's average Book Value Per Share Growth Rate was -27.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -17.40% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Nkarta was -17.40% per year. The lowest was -17.40% per year. And the median was -17.40% per year.

Back to Basics: PB Ratio


Nkarta PB Ratio Historical Data

The historical data trend for Nkarta's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta PB Ratio Chart

Nkarta Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 6.24 2.02 0.79 1.19

Nkarta Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.50 0.34 0.23 1.19

Competitive Comparison of Nkarta's PB Ratio

For the Biotechnology subindustry, Nkarta's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nkarta's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's PB Ratio distribution charts can be found below:

* The bar in red indicates where Nkarta's PB Ratio falls into.



Nkarta PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Nkarta's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=6.25/5.557
=1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Nkarta  (NAS:NKTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Nkarta PB Ratio Related Terms

Thank you for viewing the detailed overview of Nkarta's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nkarta (Nkarta) Business Description

Traded in Other Exchanges
N/A
Address
6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Executives
Paul J Hastings director, officer: See Remarks 61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook officer: Chief Medical Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager officer: Chief Legal Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Ralph Brandenberger officer: Sr. VP, Technical Operations 6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager officer: Chief Scientific Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alyssa Levin officer: See Remarks 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood officer: Chief Business Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Angela Thedinga director C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam officer: Chief Medical Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900